Compare Transocean Ltd (RIG) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Transocean Ltd vs ResMed Inc. — how do they compare? Transocean Ltd trades at $5.29 (market cap $5.80B), while ResMed Inc. trades at $193.21 (market cap $28.40B). The key difference: ResMed Inc. is far larger — about 4.9× Transocean Ltd's market cap, and ResMed Inc. pays a 1.23% dividend while Transocean Ltd pays none. Which is the better fit depends on your goals.
| RIG | RMD | |
|---|---|---|
Market Cap | $5.80B | $28.40B |
Sector | Technology | Health |
52-Week High | $7.58 | $293.73 |
52-Week Low | $2.80 | $182.82 |
Enterprise Value | $10.74B | $27.58B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Transocean Ltd. (RIG) trades at $5.02, down 2.33% today, reflecting ongoing investor caution despite recent contract wins. The stock shows a bearish technical bias with moving averages signaling sell pressure, while fundamentals reveal persistent net losses (-$2.92B in 2025) despite high gross margins (84.88%). Recent news highlights a $1B+ Equinor contract and pending Valaris merger, boosting long-term revenue visibility but failing to offset near-term profitability concerns.
RIG's investment case hinges on backlog execution and merger synergies, offering potential upside to the $7.00 consensus target. However, high leverage, volatile oil prices, and consecutive earnings misses pose significant risks. Analyst sentiment is divided (39% Buy, 39% Hold), suggesting cautious optimism amid operational challenges.
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Transocean Ltd
Transocean Ltd. is a leading international provider of offshore contract drilling services for oil and gas wells. The company operates one of the world's most versatile fleets of mobile offshore drilling units, including ultra-deepwater drillships and harsh environment semi-submersibles. RIG's services are essential to energy exploration and production companies seeking to access deepwater and challenging reserves globally.
Read more on RIG →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
